New drug aims to supercharge immune system against Hard-to-Treat cancers
NCT ID NCT06302426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing a new drug called INI-4001, which is designed to activate the immune system to fight advanced solid tumors. About 50 adults with cancers that have spread or cannot be removed will receive the drug alone or combined with standard immunotherapy drugs like nivolumab or pembrolizumab. The main goal is to find the safest dose and check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INI-4001 (a drug that activates the immune system to attack tumors), given alone or with nivolumab or pembrolizumab
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors by boosting the body's immune response.
What could go wrong
This is a very early Phase 1 trial with only 50 people, so it may not work or could have side effects. The main goal is just to find a safe dose, not to prove effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cabrini Hospital
RECRUITINGMalvern, Victoria, 3144, Australia
Contact Email: •••••@•••••
Contact
-
Southern Oncology Clinical Research Unit
RECRUITINGBedford Park, South Australia, 5042, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Border Cancer Hospital
RECRUITINGAlbury, New South Wales, 2640, Australia
Contact
Contact Email: •••••@•••••